SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:lup.lub.lu.se:a67e30ac-8154-4dba-a554-31c88a68667d"
 

Sökning: id:"swepub:oai:lup.lub.lu.se:a67e30ac-8154-4dba-a554-31c88a68667d" > The SGLT2 inhibitor...

The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice

Vercalsteren, Ellen (författare)
Karolinska Institutet,Karolinska Institute
Karampatsi, Dimitra (författare)
Karolinska Institutet,Karolinska Institute
Buizza, Carolina (författare)
Lund University,Lunds universitet,Translationell Neurologi,Forskargrupper vid Lunds universitet,Translational Neurology (TNY),Lund University Research Groups
visa fler...
Nyström, Thomas (författare)
Karolinska Institutet,Karolinska Institute
Klein, Thomas (författare)
Boehringer Ingelheim GmbH
Paul-Visse, Gesine (författare)
Lund University,Lunds universitet,Translationell Neurologi,Forskargrupper vid Lunds universitet,Regeneration in Movement Disorders,Translational Neurology (TNY),Lund University Research Groups
Patrone, Cesare (författare)
Karolinska Institutet,Karolinska Institute
Darsalia, Vladimer (författare)
Karolinska Institutet,Karolinska Institute
visa färre...
 (creator_code:org_t)
2024
2024
Engelska.
Ingår i: Cardiovascular Diabetology. - 1475-2840. ; 23
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are potent anti-diabetic drugs that also efficiently reduce cardiovascular death and heart failure. In addition, SGLT2i facilitate several processes implicated in stroke recovery. However, the potential efficacy of SGLT2i to improve stroke recovery in T2D has not been investigated. Therefore, we determined whether a post-stroke intervention with the SGLT2i Empagliflozin could improve stroke recovery in T2D mice. T2D was induced in C57BL6J mice by 8 months of high-fat diet feeding. Hereafter, animals were subjected to transient middle cerebral artery occlusion and treated with vehicle or the SGLTi Empagliflozin (10 mg/kg/day) starting from 3 days after stroke. A similar study in non diabetic mice was also conducted. Stroke recovery was assessed using the forepaw grip strength test. To identify potential mechanisms involved in the Empagliflozin-mediated effects, several metabolic parameters were assessed. Additionally, neuronal survival, neuroinflammation, neurogenesis and cerebral vascularization were analyzed using immunohistochemistry/quantitative microscopy. Empagliflozin significantly improved stroke recovery in T2D but not in non-diabetic mice. Improvement of functional recovery was associated with lowered glycemia, increased serum levels of fibroblast growth factor-21 (FGF-21), and the normalization of T2D-induced aberration of parenchymal pericyte density. The global T2D-epidemic and the fact that T2D is a major risk factor for stroke are drastically increasing the number of people in need of efficacious therapies to improve stroke recovery. Our data provide a strong incentive for the potential use of SGLT2i for the treatment of post-stroke sequelae in T2D.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Neurologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Neurology (hsv//eng)

Nyckelord

diabetes
stroke
pericytes

Publikations- och innehållstyp

art (ämneskategori)
ref (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy